{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-24-000004","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.800139+00:00","generated_at":"2026-06-07T02:18:36.008046+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical Systems Q4 preliminary revenue ~$192.4M (+40% YoY); FY2024 guidance $775-785M","bullets":["Q4 2023 revenue expected $192.3-192.5M, ~40% increase over Q4 2022.","FY2023 revenue expected $624.6-624.8M, ~53% increase over FY2022.","Added 78 new U.S. centers in Q4, total 1,180; 13 new sales territories, total 287.","Initial FY2024 revenue guidance $775-785M, 24-26% growth over FY2023.","Company expects to report a profitable Q4 when full results are released Feb 6, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-24-000004","json":"https://secwatch.observer/filing/0001609550-24-000004.json","markdown":"https://secwatch.observer/filing/0001609550-24-000004.md","text":"https://secwatch.observer/filing/0001609550-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000004/0001609550-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000004/insp-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:18:36.008046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"597686b51bae4e7a366529ce30ef3c6b6c059c5c","claim":"Inspire Medical Systems, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million. Guidance initiated.","evidence_excerpt":"Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000004/0001609550-24-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}